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The rapid advance of stem cell clinical trials for a broad 
spectrum of conditions warrants an update of the review 
by Trounson (2009) [1]. There has been a rapid surge in 
clinical trials involving stem cell therapies over the last 
two to three years and those trials are establishing the 
clinical pathways for an emergent new medicine. These 
early  trials  are  showing  roles  for  stem  cells  both  in 
replacing  damaged  tissue  as  well  as  in  providing 
extracellular  factors  that  can  promote  endogenous 
cellular salvage and replenishment.
Bone marrow, umbilical cord blood, placental and 
mesenchymal stem cells
There  are  many  studies  involving  autologous  therapies 
and some allogenic therapies, based on the recovery of 
mobilized  bone  marrow  cells,  including  mesenchymal 
stem  cells  (MSCs)  and  adipose  derived  stem  cells  that 
also include the stromal or adherent cell type that has an 
MSC phenotype. Human umbilical cord blood cells have 
been  used  in  a  large  number  of  trials  for  paraplegia, 
ataxia,  multiple  sclerosis,  amyotrophic  lateral  sclerosis, 
cerebrovascular disease, multiple system atrophy, motor 
neuron disease, among other indications, without severe 
immunological response [2]. Placenta-derived stem cells 
are being considered for similar uses and are in Phase III 
clinical trial for critical limb ischemia by Israel’s Pluristem 
Therapeutics.
A  significant  proportion  of  clinical  studies  that  are 
underway  involve  bone  marrow  and  cord  blood  stem 
cells for blood and immune disorders [3] and cancers. 
Several of those are now considered applicable for patient 
treatments beyond the need for regulated clinical trials. 
We  have  chosen  to  concentrate  on  the  emerging 
therapeutics  that  broadly  involves  a  wide  range  of  cell 
types  in  clinical  trials  registered  on  the  National 
Institutes of Health’s clinical trials web site.
MSCs are a stromal cell type and the current definition 
of  MSCs  includes  plastic  adherence  in  cell  culture, 
specific surface antigen expression (CD105(+)/CD90(+)/
CD73(+),  CD34(-)/CD45(-)/CD11b(-)  or  CD14(-)/
CD19(-) or CD79α(-)/HLA-DR1(-)), and multi-lineage in 
vitro differentiation potential (osteogenic, chondrogenic, 
and  adipogenic)  [4].  The  public  clinical  trials  database 
http://clinicaltrials.gov  shows  123  clinical  trials  using 
MSCs for a very wide range of therapeutic applications 
(Figure 1), the majority of which are in Phase I (safety 
studies), Phase II (proof of concept for efficacy in human 
patients),  or  a  mixture  of  PhaseI/II  studies  (Figure  2). 
This  includes  bone  and  cartilage  repair,  cell  types  into 
which MSCs readily differentiate, and immune conditions 
such  as  graft  versus  host  disease  and  autoimmune 
conditions  that  utilize  the  MSC’s  immune  suppressive 
properties. Expectations for patient benefits are high in 
these  therapeutic  applications.  Nevertheless,  there  are 
many prospective applications where the mechanism of 
action  is  not  obvious  and  some  concerns  have  been 
expressed  about  the  likelihood  of  long-term  benefit  of 
these applications. In the case of allogenic MSCs, delivery 
to an inflamed site can result in gain of immune potency 
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mediated inflammatory response [5].
Cardiac repair
The  use  of  patient’s  own  bone  marrow  aspirates, 
hematopoietic  stem  cells  and  MSCs,  for  heart  muscle 
tissue repair can be puzzling because these cells do not 
normally contribute to the cardiac lineage types that are 
desired.  There  is  some  preclinical  data  in  support  of 
umbilical cord blood for improved cardiac function for 
myocardial infarction [6] but sustained patient recovery 
has not been clearly demonstrated. It has been shown, 
that  these  blood  and  stromal  cells  may,  in  vitro,  form 
sarcomeric  structures  typical  of  cardioimyocytes  with 
expression of some genes expected of these cell types: 
atrial natriuretic peptide (ANP), brain natriuretic peptide 
(BNP), and contractile proteins including myosin heavy 
chain, myosin light chain, and alpha actin [7]. There is 
little  evidence,  however,  of  myocardial  regeneration 
in vivo, despite 3% to 4% (range 2% to 7%) improvement 
in the global left ventricular function and cardiac ejection 
fraction  (contractility),  but  not  left  ventricular 
remodeling,  in  meta-analyses  following  intracoronary 
infusions for myocardial infarction [7-9]. In comparative 
studies  of  MSCs  and  cardiac  (c-kit+)  stem  cells  and 
cardiosphere  derived  cells,  [10]  the  cardiomyogenic 
differentiation  capacity  was  clearly  more  effective  with 
the  cardiac  derived  cells  than  with  MSCs.  There  is  a 
distinct  possibility  that  procedure-related  variables 
influence the positive outcomes for patients. So there is a 
need to optimize treatment timing, cell type and dose, 
and delivery methods. Also research needs to determine 
the potential tropic influence of stem cell secretions or 
cytokines released at the site of injury and the degree of 
cardio-repair  that  may  be  clinically  relevant  [11].  A 
recent study by Lee and colleagues at Harvard found a 
subset  of  marrow  cells  that  was  able  to  stimulate 
endogenous adult cardiac stem cells, offering a possible 
mechanism  for  the  effect  seen  [12].  It  is  possible  that 
protein-based  rather  than  cell-based  therapies  may 
evolve from these studies. It is pretty clear that for the 
ventricular remodeling required, more effective cell types 
with  significant  populating  capacity  will  be  needed  to 
replace the severely damaged infarct area of the heart.
Neurological applications
Studies involving umbilical cord blood for neurological 
indications have been promoted as a result of preclinical 
data on the apparent formation of neurons in vitro [13] 
but there is little evidence of their transdifferentiation to 
functional  neurons  or  glial  cells  in  vivo.  Mobilized 
peripheral blood cells (CD34+) delivered into the femoral 
artery have been used in safety studies for chronic spinal 
cord injury without adverse effects but with very little 
evidence of efficacy in follow up [14].
Clinical trials involving use of MSCs for the treatment 
of  neurological  disorders  is  also  relatively  common 
(Figure 1), despite little evidence for their conversion to 
neural cells in vivo. Autologous MSCs isolated from bone 
marrow  and  injected  intrathecally  into  spinal  cord 
cerebrospinal  fluid,  allowing  access  to  the  brain  and 
spinal  column,  can  be  accomplished  safely  in  patients 
with multiple sclerosis and amyotrophic lateral sclerosis 
(ALS). Karussis et al. (2010) [15] provided some evidence 
of immunomodulatory effects of MSCs within 24 hours 
of intrathecal injection but claims of ferumoxides labeled 
MSCs  persisting  after  three  to  six  months  was  less 
persuasive.
Immunological applications
Multiple  sclerosis  is  currently  treated  with  steroids, 
immunomodulating  agents,  immunosuppression  and 
humanized  monoclonal  antibodies  (Natalizumab)  and 
Figure 1. Diseases being addressed using mesenchymal stem 
cells (MSC) for clinical trials (n=number of trials)
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transplantation  of  autologous  CD34+  hematopoietic 
stem  cells  (HSCs)  aimed  to  reconstitute  the  immune 
system  following  the  removal  of  active  autoreactive  T 
cells. This would enable the establishment of tolerance to 
autoantigens and a period of remission in diseases such 
as multiple sclerosis. With more than 400 patients treated 
in Phase I/II trials there is benefit seen in inflammatory 
parameters  and  disease  progression,  particularly  in 
rapidly evolving severe multiple sclerosis [16]. Whether 
these  early  improvements  in  clinical  parameters  of 
disability  will  translate  into  long-term  benefits  and 
sustained remission is as yet unclear. There are strong 
recommendations to undertake randomized comparative 
trials of HSC transplantation versus non-transplantation 
with  a  large  target  patient  population  to  validate  any 
benefit for HSC therapy [17]. Given the need for strong 
immunosuppression as part of the strategy, the benefits 
need to substantially outweigh the risks inherent in the 
treatment. There have been some studies using allogenic 
HSCs  but  none  are  currently  reported  active.  This 
approach is only considered in advanced nonmalignant 
disease because of unfavorable risk to benefit ratio [17]. 
Further  study  is  warranted  for  HSC  therapy  in  these 
patients.
Systemic  sclerosis,  systemic  lupus  erythematosus  and 
Crohn’s Disease as well as multiple sclerosis, are major 
disease  targets  for  multinational  randomized  clinical 
trials. Improvements are observed in dermal fibrosis and 
pulmonary  dysfunction  in  systemic  sclerosis  patients 
following lymphoablative conditioning and HSC therapy 
up to 8 years [18]. There are also trials evaluating HSC 
therapy  in  rheumatoid  arthritis  and  juvenile  idiopathic 
arthritis  [19].  These  approaches  all  focus  on  transient 
depletion  of  active  immune  cell  numbers  followed  by 
qualitative  changes  in  the  immune  cell  repertoire  that 
enables  the  resetting  of  a  modified  adaptive  immune 
system that is tolerant to self-antigens, previously targeted 
in  autoimmune  disease.  While  present  clinical  trial 
approaches using autologous HSCs will be informative, it 
remains speculative whether long-term remission will be 
achieved in the variety of diseases under examination and 
improvements  in  therapeutic  strategies  are  expected  to 
evolve  in  time.  The  potential  use  of  MSCs  in  resetting 
immune homeostasis as a therapeutic approach is being 
explored because of their ability for cytoprotection and 
immunosuppression. However, their long-term usefulness 
and exact role in the treatment of autoimmune diseases 
remains to be determined.
Chronic Graft Versus Host Disease (GVHD) has also 
been  a  target  for  HSC  and  MSC  cell  therapies  and  is 
usually  observed  after  allogenic  HSC  or  tissue 
transplants. This very serious condition may manifest in 
the peripheral or central nervous systems, and in multiple 
organs of the body [20]. At least ten clinical trials with 
MSC have been reported with mixed results, but many 
show  a  significant  level  of  positive  response.  One 
company,  Osiris,  has  completed  patient  enrollment  in 
Phase 3 trials for steroid refractory acute GVHD and for 
newly diagnosed acute GVHD [21].
Genetic blood diseases
HSC therapies are in clinical trials for genetic diseases 
such as sickle cell disease and b-thalassemia. In sickle cell 
disease, curative high levels of T-cell chimerism (>50%) 
using  HLA-matched  sibling  allogenic  CD34+  HSC 
transplantation  can  be  achieved  without  myloablation 
[22]. New developments in stem cell gene therapy offer a 
potentially  safer  therapy  for  sickle  cell  disease  in  the 
future [23].
Long-term mixed chimerism with allogenic HSCs can 
be achieved in b-thalassemia but it is recommended that 
the  donor  chimerism  be  >25%  for  robust  therapeutic 
effects  in  these  patients  [24].  However,  gene  therapy 
models involving the transduction of CD34+ HSCs with 
lentiviral vectors indicate that only 10% to 15% chimerism 
of functional thalassemic cells can be achieved which is 
below  the  therapeutically  curative  level  [24].  Even  the 
recovery  of  CD34+  cells  for  gene  therapy,  using 
granulocyte-colony stimulating factor (G-CSF) stem cell 
mobilization may be harmful in b-thalassemia patients, 
and may cause severe side effects in sickle cell anemia 
patients.  This  needs  careful  evaluation  and  additional 
consideration to minimize these adverse risks [25].
Allogenic  HSC  therapy  in  cases  of  inherited  genetic 
disease  may  be  associated  with  death  or  severe 
complications  after  transplantation  making  autologous 
gene therapy for blood and immune disease an important 
strategy. Boztug et al [26], have shown that HSC gene 
therapy for Wiskott-Aldrich syndrome, a severe X-linked 
recessive  immunodeficiency  disorder,  can  be  largely 
corrected by autologous HSC gene therapy. CD34+ cells 
from  two  patients  were  transduced  with  a  retroviral 
vector incorporating a construct expressing the correct 
gene  (WASP)  after  transient  mylosuppression  with 
busulfan.  Stable  chimerism  of  9%  and  20%  of  donor 
hematopoietic  progenitors  were  sufficient  to  effect 
correction of the primary disease phenotype, including 
hemorrhagic  diathesis,  eczema,  autoimmunity,  and 
severe infection. These types of clinical studies lay the 
foundation for stem cell gene therapy in human disease. 
This will likely include the potential cure of HIV/AIDS by 
targeted  disruption  of  the  CCR5  gene  in  autologous 
CD34+ HSCs [27].
Adipose stem cells
Adipose  stem  cells  are  plentiful  and  relatively  easily 
accessed.  They  have  been  shown  to  be  useful  for  soft 
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cells  (ASCs)  (CD31-/CD34+/CD45-/CD90+/CD105-/
CD146-),  endothelial  progenitor  cells  and  pericytes. 
Autologous ASCs and the stromal vascular fractions are 
being  used  for  soft  tissue  engineering  with  a  range  of 
scaffolds, particularly for breast augmentation, fistulas in 
Crohn’s disease and tissue damaged by radiation [28].
In addition to soft tissue repair, ASCs are also in clinical 
trial  for  myocardial  infarction  and  graft  versus  host 
disease,  with  outcomes  equivalent  to  MSCs  [29].  They 
have  also  been  used  in  clinical  trials  for 
tracheomediastinal  fistula,  Calvarial  bone  defect,  skin 
ulcer and stress induced urinary incontinence.
The relative advantage of ASCs over MSCs remains to 
be determined for the variety of applications envisaged 
and further studies may demonstrate the merits of ASCs. 
Meanwhile,  soft  tissue  repair  and  fistula  repair  will 
remain a primary application of ASCs for the immediate 
future.
Endothelial stem cells
Endothelial progenitor cells (CD34+/CD133+/KDR+ or 
VEGFRII+) may be sourced from several sources inclu-
ding  bone  marrow,  umbilical  cord  blood  and  adipose 
tissue.  They  are  effective  in  the  stimulation  of  angio-
genesis and in clinical studies requiring revascularization 
and remodeling of collaterals in atherosclerotic cardio-
vascular disease. The result desired is the regeneration of 
damaged  tissues,  preventing  amputation  of  ischemic 
limbs  and  other  areas,  and  recovery  after  myocardial 
infarction. While efficacy in preclinical trials and safety 
in Phase I studies has been demonstrated, unequivocal 
evidence for patient benefit in placebo-controlled trials 
has  not  been  obtained  [30].  The  role  of  endothelial 
progenitor cells (EPCs) in neoangiogenesis of plexiform 
lesions remains uncertain and there is continuing debate 
about the function of EPCs in the regenerative processes 
that are the target of EPC therapy. These matters require 
careful consideration in future clinical trials [31].
Pancreatic β islet cells
Transplantation  of  pancreatic  b  Islet  cells  has  been 
recently  reviewed  by  Matsumoto  [32].  Approximately 
70%  of  Type  I  diabetes  patients  can  achieve  insulin 
independence but may have difficulty in maintaining this. 
They also have problems due to immunosuppression and 
generally  there  is  a  shortage  of  donors  (patients  need 
multiple  donors).  Xenotransplants  of  pig  islets  using 
encapsulation  to  address  immune  rejection  is  moving 
towards the clinic but concerns still exist for transmission 
of porcine endogenous retrovirus. The use of embryonic 
stem  cell  derived  b  Islets  in  special  subcutaneous 
capsules  that  induce  minimal  fibrosis  may  evolve  into 
clinical trials shortly [33].
Neural stem cells
Neural stem cells (NSCs) may be sourced from the fetal, 
neonatal or adult brain. They self renew and differentiate 
to neurons, astrocytes and oligodendrocytes and are used 
in a variety of indications (Table 1). Clinical trials have 
been undertaken for the use of fetal neural stem cells for 
lysosomal storage diseases. Children with advanced stage 
Batten’s disease (neuronal ceroid lipofuscinosis) tolerated 
high  doses  of  NSCs  in  multiple  sites  in  the  brain 
in  Phase  I  studies.  The  transplanted  cells  provide 
widespread global replacement enzyme, renewal for cell 
replacement  and  bystander  neuroprotection  [34].  The 
Californian  company  StemCells  Inc.  embarked  on  a 
second  safety  and  efficacy  study  in  children  with  less 
advanced  Batten’s  disease  using  CD133+  cell  culture 
expanded NSCs, but discontinued the study because of 
failure  to  enroll  patients  meeting  study  criteria.  The 
company is also carrying out a Phase 1 clinical trial using 
fetal neural stem cell brain transplantation for Pelizaeus-
Merzbacher  disease  (PMD),  a  mylination  disorder  that 
affects  male  children.  Preclinical  trials  showed  NSCs 
produce  oligodendrocytes  that  remylinate  neurons 
affected by the mutated gene for PMD.
Fetal  NSCs  are  also  being  used  for  treatment  of 
disabled  ischemic  stroke  patients  by  the  company 
ReNeuron in the UK. The NSCs have a conditional form 
of the oncogene encoding c-Myc under the control of an 
estradiol  receptor  that  activates  propogation  for 
manufacture. Patients are transplanted with these NSCs 
6  to  24  months  after  stroke  using  a  straight-forward 
neurosurgical  implantation  into  the  brain.  The  NSCs 
express several trophic and pro-angiogenic factors that 
Table 1. Neural stem cell (NSC) clinical trials underway
NSC Clinical Trials 
Regenerative, Cell Replacement
StemCells Inc., CA  HuCNS-SC® (fetal derived human NSCs) 
Phase I – completed  Batten’s Disease (NCL)  USA
Phase Ib   Discontinued for lack of enrollment 
Phase I  Pelizaeus-Merzbacher Disease (PMD)  USA
Phase I/II  Chronic Spinal Cord Injury  Switzerland
NeuroGeneration, CA  Autologous NSC-derived Neurons 
Phase I – completed  Advanced Parkinson’s Disease  USA
Phase II – clinical hold   
Neuralstem Inc., MD  Fetal derived hu spinal cord SCs 
Phase I  ALS (Lou Gehrig’s Disease)  USA
ReNeuron, UK  ReN001 Immortalized huNSCs 
Phase I  Stroke  UK
Targeted Delivery of Therapeutics
City of Hope, CA  HB1.F3.CD Immortalized hu NSCS 
Phase I  Recurrent High Grade Glioma  USA
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ischemic stroke. The NSCs also have immunosuppressive 
properties  that  are  anti-inflammatory  that  would  aid 
tissue repair but they are not a persistent graft.
Studies utilizing NSCs from StemCells Inc. for chronic 
thoracic spinal cord injury are beginning clinical trial in 
Switzerland  in  2011.  The  NSCs  are  injected  into  the 
spinal  cord  and  migrate  to  the  area  of  injury  to  form 
neurons and oligodendrocytes, critical for remylinating 
damaged neuronal axons for recovery of nerve function.
Fetal  NSC  preparations  are  in  clinical  trial  by  the 
company  Neuralstem  for  the  treatment  of  ALS  (Lou 
Gehrig’s  disease).  The  NSCs  are  injected  into  multiple 
(five to ten) grey matter sites of the lumbar region of the 
spinal cord. The first six non-ambulatory patients showed 
no  adverse  effects  of  NSC  engraftment.  The  aim  is  to 
protect healthy neural cells and repair those that have 
ceased  communication  with  the  patient’s  muscles  and 
return ambulatory function.
Autologous NSCs obtained from patient brain biopsies 
have  been  used  to  treat  Parkinson’s  disease  by  the 
company NeuroGeneration Inc., which has trial sites in 
California  (University  of  California  Los  Angeles  and 
Cedars-Sinai Medical Center), Italy (University of Milan) 
and Estonia (University of Tallin). Biopsied brain tissue is 
cultured in vitro for several months and the expanded 
neural stem cells differentiated into neurons, astrocytes 
and oligodendrocytes. These include GABAnergic (60%) 
and dopaminergic (15%) neurons and the mixed neurons 
and  glia  are  implanted  at  multiple  sites  in  the  post-
commissural  putamen.  Patients  showed  some  motor 
recovery (not always sustained) and increased dopamine 
uptake in the transplanted putamen and clinical benefits 
that persist [35]. Further Phase II studies are presently on 
hold while manufacturing methods are established.
NSCs are also entering clinical trials for targeting the 
destruction  of  inoperable  gliobastoma.  NSCs  home  to 
tumors and scientists at the City of Hope, California are 
genetically modifying the NSCs so they produce a pro-
drug  activating  enzyme  (cytosine  deaminase)  that 
converts a non-toxic prodrug (5-Fluorocytosine, 5-FC) to 
a cytotoxic anticancer drug (5-Fluorouracil, 5-FU). The 
high local cytotoxicity will destroy gioblastomas. This is a 
very aggressive disease and patients are under treatment 
in the initial Phase I/II study.
Limbal stem cells
Corneal  disease  is  the  second  most  common  cause  of 
blindness. Corneal epithelial stem cells are located at the 
basal  layer  of  the  limbus  epithelium  and  provide  for 
replacement  of  corneal  epithelial  cells  that  are  lost  or 
damaged.  Limbal  cell  deficiency  can  be  treated  with 
transplanted limbal stem cells taken as a small biopsy and 
expanded  ex  vivo.  Patients  treated  with  expanded 
autologous  limbal  stem  cells  transplanted  on  human 
amniotic  membrane  had  stable  corneal  epithelium 
reconstruction  in  all  their  eyes  with  improvement  in 
visual acuity in the majority [36]. This appears to be a safe 
and  effective  way  of  restoring  vision  in  limbal  cell 
deficiency.
Myoblasts
Regeneration  of  skeletal  muscle  in  cases  of  muscular 
dystrophy  depends  on  satellite  cells  or  myogenic 
progenitors that are localized between the basal lamina 
and  muscle  fiber  membrane  [37].  Transplant  trials  of 
satellite  cells  or  expanded  myocytes,  injected  into 
muscles of patients with muscular dystrophy were shown 
to be safe and in some cases new dystrophin production 
was observed but clinical benefits were not demonstrated 
[35]. The problem appears to be in the need for massive 
numbers of injections because satellite cells distribute at 
local injection sites, with rapid cell loss. Also, immune 
responses were seen even with compatible cells, resulting 
in patients requiring immunosuppression [38].
The  use  of  myoblasts  for  cardiac  repair  has  been 
disappointing because skeletal muscle doesn’t integrate 
functionally  with  cardiomyocytes,  leading  to  a  high 
incidence of arrhythmias [37].
Hepatocytes
Hepatocyte transplantation is currently most successful 
for  liver  based  metabolic  disorders,  for  example  to 
replace  a  deficient  enzyme.  This  includes  familial 
hyper-cholesterolemia,  where  autologous  hepatocytes 
transduced  with  the  low-density  lipoprotein  (LDL) 
receptor gene showed engraftment and 20% reduction in 
LDL cholesterol in three of five patients [39]. Allogenic 
hepatocyte  transplantation  has  also  been  undertaken 
with some partial success for metabolic disorders with a 
few  reports  of  long-term  function  of  transplanted 
hepatocytes  [39,  40].  Hepatocytes  are  usually  injected 
into the portal venous system and engraftment is most 
common in the liver or spleen.
Pluripotent stem cells
Human  embryonic  stem  cells  (hESCs)  have  begun  to 
make their way through to Phase I clinical trials (Table 2) 
with  Geron’s  oligodendrocyte  precursor  cells  derived 
from hESCs leading the field for safety studies on thoracic 
spinal cord injury. In this study, the patients need to have 
documented  evidence  of  functionally  complete  spinal 
cord  injury  at  the  T3  to  T10  spinal  segments.  The 
oligodendrocyte progenitors are grafted into the spinal 
cord  at  the  site  of  injury  with  short-term  mild 
immunosuppression. The company plans to extend the 
indication  to  high  cervical  injury,  which  is  far  more 
common, after the completion of the initial safety studies. 
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company  addressed  the  occurrence  of  micro-cysts  in 
animal  transplants  and  screened  cell  line  products  for 
freedom of this characteristic.
The  company  Advanced  Cell  Technology  (ACT,  CA 
and  MA)  has  Phase  I/II  approval  for  clinical  trials  on 
Stargardt’s Macular Dystrophy, which is a condition of 
blindness that arises through a photoreceptor cell protein 
anomaly  that  causes  degeneration  of  the  underlying 
retinal epithelium monolayer and subsequent loss of the 
photoreceptor  cells.  They  have  derived  pigmented 
epithelial progenitor cells that may be injected under the 
photoreceptor  cells  to  redevelop  the  polarized  retinal 
epithelium monolayer. Since the primary defect is in the 
photoreceptor  cells,  it  is  possible  that  the  new  retinal 
epithelium  will  be  lost  in  time  and  require  repeat 
grafting.  Short-term  immunosuppression  is  to  be  used 
for grafts of allogenic retinal progenitors to the eye, even 
though this is considered an immune privileged site.
ACT also has approval for use of the same cells for a 
Phase  I/II  study  of  dry  macular  degeneration.  This  a 
leading cause of loss of central vision in persons older 
than  55  years  of  age.  The  retinal  progenitors  should 
distribute to areas of retinal degeneration and potentially 
correct the loss of vision.
Conclusions
Clinical trials on the use of stem cells are underway for a 
wide variety of conditions and there is an emphasis on 
the use of bone marrow, hematopoietic (mobilized and 
recovered  in  blood  and  umbilical  cord  blood)  and 
mesenchymal  stem  cells.  While  safety  has  been 
consistently demonstrated, particularly with autologous 
transplants,  sustained  curative  benefit  has  not  been 
consistently  obtained.  Allogenic  transplants  generally 
have major issues for continual immunosuppression to 
prevent  rejection  of  grafted  cells.  In  some  cases,  the 
benefit  of  cell  therapy  is  through  unidentified  trophic 
effects of transient grafted cells. Nevertheless, progress 
for therapeutic benefit for patients is increasing and there 
is clear merit for using stem cells as delivery vehicles for 
correcting  genetic  mutations  that  cause  severe  disease 
phenotypes. Increasingly, new stem cell types are being 
explored  and  both  neural  and  pluripotent  stem  cells 
(embryonic stem cells) are under study in early Phase I/II 
trials. It is too early to predict the outcome of these trials 
at present but early observations of patients indicate that 
they do appear to be safe. Recent studies using induced 
pluripotent  stem  cells  (iPSCs)  have  shown  sizeable 
genetic and epigenetic abnormalities in these cells and 
there  is  now  a  clear  need  to  determine  the  biological 
significance of those changes before iPSCs are taken to 
clinical  trials  [41,  42].  A  strong  indication  of  the 
confidence  in  the  cell  therapy  field  is  the  increasing 
participation of the large pharmaceutical companies in 
stem  cell  therapies  [43].  Strong  funding  from 
organizations  such  as  the  Californian  Institute  for 
Regenerative Medicine and their collaborating partners 
worldwide is likely to rapidly expand new clinical trials in 
the next few years.
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